The pathways most affected by the NEFA treatment (pathways which had low p-values) were “Clathrin-mediated endocytosis signaling”, “phospholipase C signaling”, “glucocorticoid receptor signaling”, “semaphoring signaling in neurons”, “estrogen-dependent breast cancer signaling”, “HOTAIR regulatory pathway”, “regulation of eIF4 and p70S6K signaling”, “EGF signaling”, “Huntington’s disease signaling”, and “Insulin secretion signaling pathway” (Fig. 6) (Supplemental Table S3). The gene discussed is EGF; the disease is breast carcinoma.